Novan Inc: Jumps as skin infection gel meets main goal in late-stage study

NVN Liquidation

11/06/2021 11:53

** Biotech co's  NOVN.O  shares jump 45% to $13.11 premarket
    ** Co says late-stage study of SB206, its topical antiviral
gel for treating contagious skin infection molluscum
contagiosum, met its main goals with positive safety and
efficacy data  urn:newsml:reuters.com:*:nGNX11MRYg
    ** Study conducted in 891 patients across 55 clinical sites
- NOVN
    ** Co plans to submit new drug application for the gel by Q3
2022       
    ** The infection is caused by the molluscipoxvirus,
affecting about six mln people in the United States annually,
with the greatest incidence among children under 14 years - NOVN
    ** As of last close, stock up about 11% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))